DAURISMO for Acute Myeloid Leukemia

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.
— Read on www.pharmacytimes.com/publications/directions-in-pharmacy/2019/september2019/https//www.pharmacytimes.com/

Another inhibitor for oncology.

Leave a Reply

Your email address will not be published. Required fields are marked *